- Home
- ACNB vs BCYC Comparison
ACNB vs BCYC Comparison
Compare ACNB & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACNB
- BCYC
- Stock Information
- Founded
- ACNB 1857
- BCYC 2009
- Country
- ACNB United States
- BCYC United Kingdom
- Employees
- ACNB N/A
- BCYC N/A
- Industry
- ACNB Major Banks
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- ACNB Finance
- BCYC Health Care
- Exchange
- ACNB Nasdaq
- BCYC Nasdaq
- Market Cap
- ACNB 468.6M
- BCYC 438.4M
- IPO Year
- ACNB N/A
- BCYC 2019
- Fundamental
- Price
- ACNB $49.50
- BCYC $6.86
- Analyst Decision
- ACNB Strong Buy
- BCYC Buy
- Analyst Count
- ACNB 3
- BCYC 11
- Target Price
- ACNB $50.67
- BCYC $18.73
- AVG Volume (30 Days)
- ACNB 19.7K
- BCYC 392.5K
- Earning Date
- ACNB 10-23-2025
- BCYC 10-30-2025
- Dividend Yield
- ACNB 3.08%
- BCYC N/A
- EPS Growth
- ACNB N/A
- BCYC N/A
- EPS
- ACNB 3.34
- BCYC N/A
- Revenue
- ACNB $136,676,000.00
- BCYC $28,339,000.00
- Revenue This Year
- ACNB $41.47
- BCYC N/A
- Revenue Next Year
- ACNB $3.31
- BCYC N/A
- P/E Ratio
- ACNB $14.78
- BCYC N/A
- Revenue Growth
- ACNB 28.45
- BCYC N/A
- 52 Week Low
- ACNB $35.70
- BCYC $6.03
- 52 Week High
- ACNB $49.72
- BCYC $21.50
- Technical
- Relative Strength Index (RSI)
- ACNB 65.89
- BCYC 48.60
- Support Level
- ACNB $45.64
- BCYC $6.03
- Resistance Level
- ACNB $48.90
- BCYC $6.75
- Average True Range (ATR)
- ACNB 1.30
- BCYC 0.41
- MACD
- ACNB 0.12
- BCYC 0.04
- Stochastic Oscillator
- ACNB 88.78
- BCYC 91.49
About ACNB ACNB Corporation
ACNB Corp provides banking, insurance, and financial services to businesses and consumers, through its wholly-owned subsidiaries, ACNB Bank and ACNB Insurance Services, Inc. The corporation has two reporting segments; the Banking segment which generates the majority of the revenue from banking and wealth management services, including trust and retail brokerage, and ACNB Insurance Services segment which offers a broad range of property and casualty, life and health insurance to both commercial and individual clients.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.